The issuance of a notice of allowance for a patent application is a significant positive development for companies, especially in the healthcare and biotech sectors. It not only enhances the company's intellectual property portfolio but also potentially opens up new revenue streams through licensing or direct application of the patented technology. For Cardio Diagnostics Holdings, this development is directly related to its core business of cardiovascular disease detection, making it highly relevant and important for investors. The positive market reaction is anticipated due to the potential for increased investor confidence and perceived future value.